BackINVO Bioscience Overview

INVO Bioscience Receivables

Latest receivables for INVO: $250M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$248.39M
↑ 43.07% YoYΔ $74.77M vs prior year quarter

Peer average

Loading

INVO Bioscience Receivables History

Loading

INVO Bioscience vs. peers: Receivables Comparison

Loading

INVO Bioscience Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

INVO Bioscience (INVO) FAQ

As of the most recent data (March 2026), INVO shows a receivables of $250M. That compares with $170M in the prior-year period — up 43.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INVO's receivables is now $250M (was $170M) — a 43.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether INVO Bioscience is outperforming or lagging.

Tracking INVO's receivables over time shows whether INVO Bioscience is scaling, shrinking, or reshaping that part of the business. The current reading is $250M That compares with $170M in the prior-year period — up 43.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has INVO Bioscience's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $250M) with ownership activity and broader fundamentals.

INVO Bioscience's receivables is $250M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.